Zydus Cadila keen on unit in Hyderabad Pharma City

Company sees talent pool in Hyderabad suitable for generics unit

By Author  |  Published: 11th Sep 2018  12:12 amUpdated: 10th Sep 2018  9:08 pm
Hyderabad Pharma City
The pharma company operates more than 30 production facilities across the world.

Hyderabad: Ahmedabad-based Zydus Cadila is keen on setting up a greenfield unit in the upcoming Hyderabad Pharma City. Pankaj Ramanbhai Patel, chairman, Zydus Cadila, told Telangana Today, “In future, we will surely look at Hyderabad to set up our unit. It depends on when the Pharma City comes up, we will decide on what specific products or therapeutic areas we should focus on.”

He added, “We could certainly look at the generics space. There is abundant talent pool in Hyderabad, which we would like to tap in future.”

Zydus Cadila today ranks fourth in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five States of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil. The group has manufacturing capabilities across the entire pharmaceutical value chain including formulations, bulk drugs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products and wellness products. It has more than 30 manufacturing plants worldwide.

Zydus’ global business has a strong presence in the regulated markets such as the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in 25 other emerging markets worldwide.

Biosimilars
The company has over 1,300 researchers across 19 sites, working on differentiated medicines from new chemical entities (NCEs) to vaccines, biosimilars and niche technologies.

Cadila Healthcare, part of Zydus Cadila group, is planning to file its first biosimilar Pegfilgrastim for approval in the US by end of next year. It is the biosimilar version of US biotech company Amgen’s drug Neulasta. The drug earned about $4.5 billion globally last year.

Biosimilars are near-identical copies of biologic drugs produced by living cells. They are complex to make and companies developing them have to test these drugs on patients to demonstrate safety and efficacy like any other new drug before it gets approved by the drug regulators. The company has already launched eight biosimilars in India. It launched the world’s first biosimilar of Adalimumab in 2015, making an impact on 12 million people suffering from auto immune disorders like rheumatoid arthritis.

Asked about harmonisation of regulations in pharma, he said, “There are efforts across the world for harmonisation of regulations under The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). All regulators have to work together.”

TS push for life sciences
Since January 2015, time of introduction of the TS-iPASS over 700 investment proposals in life sciences sector have been approved by the State Government, including more than 100 R&D proposals. And over 80 per cent of these projects have already commenced project execution. These envisage more than 20,000 high value R&D jobs and over 50,000 manufacturing jobs in the State.

The past four years have also seen the State’s life sciences sector attracting investments of about Rs 11,000 crore, including Rs 3,000 crore in R&D alone.

The contribution of life sciences sector to the overall product export value from Telangana has been 36 per cent, which has almost doubled during the last four years. The life sciences product exports in the State grew 2.41 times over the last four years, as compared to the national average of 1.18 times.